Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
TempraMed TechnologiesHAM:9DY -3.12%7 EV-to-EBITDA is -2.78 as of Sep. 12, 2026. GuruFocus rates HAM:9DY with a GF Score™ of 7/100. The stock has 5 warning signs investors should review. Among 516 Medical Devices & Instruments companies, TempraMed Technologies ranks worse than 193798.26% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TempraMed Technologies's enterprise value is €16.62 Mil.
TempraMed Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was €-5.97 Mil. Therefore, TempraMed Technologies's EV-to-EBITDA for today is -2.78.
The historical rank and industry rank for TempraMed Technologies's EV-to-EBITDA or its related term are showing as below:
HAM:9DY'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.68 Med: -8.54 Max: -2.79
Current: -2.91
During the past 3 years, the highest EV-to-EBITDA of TempraMed Technologies was -2.79. The lowest was -15.68. And the median was -8.54.
HAM:9DY's EV-to-EBITDA is ranked worse than 100% of 516
companies
in the Medical Devices & Instruments industry
Industry Median: 13.675
vs HAM:9DY: -2.91
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TempraMed Technologies's PE Ratio (TTM) for today is calculated as:
TempraMed Technologies's share price for today is €0.1865.
TempraMed Technologies's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-0.231.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, TempraMed Technologies's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TempraMed Technologies EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, TempraMed Technologies's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TempraMed Technologies's EV-to-EBITDA falls into.
TempraMed Technologies's current Enterprise Value is €16.62 Mil.
TempraMed Technologies's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €-5.97 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TempraMed Technologies (HAM:9DY) has a EV-to-EBITDA of -2.78 as of Sep. 12, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TempraMed Technologies. According to the industry distribution chart, TempraMed Technologies ranks #999999 out of 516 companies in the Medical Devices & Instruments industry.
Is TempraMed Technologies' EV-to-EBITDA too high?
TempraMed Technologies' current EV-to-EBITDA is -2.78. Based on the distribution chart, TempraMed Technologies ranks #999999 out of 516 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, TempraMed Technologies has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does TempraMed Technologies' EV-to-EBITDA compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, TempraMed Technologies ranks #999999 out of 516 companies for EV-to-EBITDA. This places TempraMed Technologies in the lower half of its industry. The industry median EV-to-EBITDA is 13.68. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 13.68, based on 516 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on TempraMed Technologies. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 13.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. TempraMed Technologies's current EV-to-EBITDA is -2.78. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TempraMed Technologies stock overvalued right now?
TempraMed Technologies (HAM:9DY) has a current EV-to-EBITDA of -2.78. The current EV-to-EBITDA is -2.78. TempraMed Technologies' overall GF Score™ is 7/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For TempraMed Technologies (HAM:9DY), the current EV-to-EBITDA is -2.78 as of Sep. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
TempraMed Technologies Ltd through its subsidiary, engaged in developing patent-protected technology designed to serve a broad range of medical and consumer products. TempraMed's primary focus is revolutionizing storage and management of injectable for temperature-sensitive medications. This inventive technology ensures adequate temperature storage conditions to medications without requiring power source or human intervention for years.
7GF Score
Get the complete analysis for HAM:9DY
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HAM:9DY has been successfully added to your 
